Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391065 | 1.00 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL2262850 | 0.79 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3259068 | 0.79 | GABRA1 (0.61) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL8801062 | 0.78 | GABRA1 (0.56) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3988229 | 0.77 | KMT2A (0.60) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL11827239 | 0.77 | PGR (0.67) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Ro-052921 SCHEMBL29979594 | 0.76 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Ro-052921 SCHEMBL1365706 | 0.76 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL8519909 | 0.76 | DAO (0.50) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL5356267 | 0.75 | GABRA1 (0.72) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1562946-B1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2010-05-26 | — | — | EP | claimed |
| US-7482337-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-27 | — | — | US | claimed |
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| CN-119528828-A | Synthesis method of methylation product of nitrogen heterocycle or oxygen heterocycle compound | 桂林理工大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-111566116-B | Novel metal complex, process for producing the same, and process for producing gamma-lactam compound using the same | 基础科学研究院 | 2023-06-09 | — | — | CN | disclosed |
| CN-111187223-B | Synthetic method of linagliptin intermediate 2-chloromethyl-4-methyl quinazoline | 沧州那瑞化学科技有限公司 | 2022-02-22 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-111187223-A | Synthetic method of linagliptin intermediate 2-chloromethyl-4-methyl quinazoline | 沧州那瑞化学科技有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7696212-B2 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH AND CO. KG (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-09 | — | — | US | disclosed |
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-6500847-B2 | RHEUMATIC DISEASES; ORAL ISEASES; VISION DEFECTS; ANTIINFLAMMATORY AGENTS | BAYER CORPORATION | 2002-12-31 | — | — | US | disclosed |
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | BAYER PHARMACEUTICALS CORPORATION | 2002-04-11 | — | — | US | disclosed |
| US-6225314-B1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | BAYER CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-5925637-A | ENZYME INHIBITORS AS ANTIARTHRITIC AGENTS OR CARDIOVASCULAR DISORDERS | BAYER CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| WO-1997043239-A9 | INHIBITION OF MATRIX METALLOPROTEASES BY 2-SUBSTITUTED-4-(4-SUBSTITUTEDPHENYL)-4-OXOBUTYRIC ACIDS | — | 1998-03-19 | — | — | WO | disclosed |
| CN-1093085-A | Sulfonamide derivatives | GLAXO GROUP LTD (GB) | 1994-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138214-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | GABRA1 2103/4885GABRA5 2468/4885GABRA3 2978/4885 |
| US-20040127500-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP26 | GABRA1 713/4885GABRA5 494/4885GABRA3 884/4885 |
| US-20100144703-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | GABRA1 2083/4885GABRA5 2164/4885GABRA3 2613/4885 |
| US-20020042417-A1 | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids | ADAMTS5, ADAMTS1, MMP13 | GABRA1 746/4885GABRA5 638/4885GABRA3 905/4885 |
| US-20090093457-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP7, DPP3 | GABRA1 2083/4885GABRA5 2164/4885GABRA3 2613/4885 |
| US-20020042418-A1 | Inhibition of matrix metalloproteases by substitued biaryl oxobutyric acides | ADAMTS5, ADAMTS1, ADAMTS4 | GABRA1 370/4885GABRA5 351/4885GABRA3 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.